Coverage


State Health Facts is a KFF project that provides free, up-to-date, and easy-to-use health data for all 50 states, the District of Columbia, and the United States. It offers data on specific types of health insurance coverage, including employer-sponsored, Medicaid, Medicare, as well as people who are uninsured by demographic characteristics, including age, race/ethnicity, work status, gender, and income. There are also data on health insurance status for a state's population overall and broken down by age, gender, and income.

View the Indicators →


Filter

121 - 130 of 1,711 Results

  • Election 2024: State Health Care Snapshots

    Feature

    These fact sheets lay out the health care landscape in every state, providing data on a variety of health care topics that may be the focus of policy debates in the 2024 election. Topics include health costs; women’s health policy, including state abortion, contraception and maternity laws and policies; health coverage, including the Affordable Care Act, Medicare and prescription drug coverage, Medicaid, and employer-sponsored insurance; gender affirming care; and basic information on health status, population and income.

  • Over-the-Counter Oral Contraceptive Pills

    Issue Brief

    Oral contraceptives are the most commonly used method of reversible contraception in the U.S. In July 2023, the FDA approved Opill, the first daily oral contraceptive pill to become available over the counter (OTC) without a doctor’s prescription. This issue brief provides an overview of OTC oral contraceptives and laws and policies related to insurance coverage.

  • Again, No Medicaid

    From Drew Altman

    In his latest column, KFF President and CEO Drew Altman explains why Medicaid, despite former President Donald Trump's silence on the topic, warrants greater attention given the potential for drastic changes or cuts to it should Republicans win control in the election.

  • How Many Adults with Private Health Insurance Could Use GLP-1 Drugs

    Issue Brief

    More than two in five (42%) or 57.4 million adults under 65 with private insurance could be eligible under clinical criteria for GLP-1 drugs used to treat people with type 2 diabetes, obesity, or excess weight and weight-related health issues, according to a new KFF analysis.